A61K39/118

SEXUALLY TRANSMITTED DISEASE VACCINES
20180296662 · 2018-10-18 · ·

The disclosure relates to sexually transmitted disease ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

SEXUALLY TRANSMITTED DISEASE VACCINES
20180289792 · 2018-10-11 · ·

The disclosure relates to sexually transmitted disease ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

SEXUALLY TRANSMITTED DISEASE VACCINES
20180289792 · 2018-10-11 · ·

The disclosure relates to sexually transmitted disease ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

MULTI-EPITOPIC CONSTRUCT
20180273608 · 2018-09-27 ·

The invention relates to multiple epitope constructs, immunogenic and vaccine compositions comprising recombinant molecules presenting inserted multiple and different epitopes from a variety of antigens. The antigenic determinants being associated with different pathways leading to atherosclerosis. In particular, the invention relates to such compositions for eliciting an immune response against antigens and pathogens involved in the development of atherosclerosis the invention includes inter alia methods of treating and/or preventing the disease and recombinant protein products

MULTI-EPITOPIC CONSTRUCT
20180273608 · 2018-09-27 ·

The invention relates to multiple epitope constructs, immunogenic and vaccine compositions comprising recombinant molecules presenting inserted multiple and different epitopes from a variety of antigens. The antigenic determinants being associated with different pathways leading to atherosclerosis. In particular, the invention relates to such compositions for eliciting an immune response against antigens and pathogens involved in the development of atherosclerosis the invention includes inter alia methods of treating and/or preventing the disease and recombinant protein products

COMPOSITIONS FOR USE IN TREATMENT OF CHLAMYDIA

This invention relates to compositions (e.g., vaccine compositions) which can be used to immunise against Chlamydia infections. The compositions comprise Chlamydia sp. antigens and antigen combinations which can be used to immunise against Chlamydia sp., used in the form of nucleic acids (e.g., mRNAs) encoding antigenic proteins or in the form of recombinant protein antigens.

COMPOSITIONS FOR USE IN TREATMENT OF CHLAMYDIA

This invention relates to compositions (e.g., vaccine compositions) which can be used to immunise against Chlamydia infections. The compositions comprise Chlamydia sp. antigens and antigen combinations which can be used to immunise against Chlamydia sp., used in the form of nucleic acids (e.g., mRNAs) encoding antigenic proteins or in the form of recombinant protein antigens.

Compositions and methods for immunodominant antigens of Mycobacterium tuberculosis

Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen M. tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.

Compositions and methods for immunodominant antigens of Mycobacterium tuberculosis

Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen M. tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.

Products and methods
10052355 · 2018-08-21 · ·

The invention relates to fungal cells and spores, as well as extracts of either, for use, in particular, in prevention or treatment of Chlamydia, or Helicobacter pylori or other infections, inflammation, inflammatory, lysosomal, acidic, SODor IgG or other immunoglobulinperoxidases or hydrogen peroxide induced or other forms of oxidative damage, atherosclerosis, heart disease, stomach, intestinal and liver inflammatory conditions and their complications, promoting or stimulating regeneration or healing of wounds, burns, ulcers, or other forms of damaged or aged tissues, or in reducing elevated cholesterol and/or triglycerides levels In a preferred instance, the fungal cells or spores are those used in the manufacture of fungal fermented cheeses or other food stuff or beverages, particular fungal blue or white cheeses.